Clinical Perspectives on Managing ILD Related to T-DXd

Author(s):

Joyce A. O'Shaughnessy, MD,Melinda L. Telli, MD

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

EP: 1.Challenges in Diagnosing HER2+ Breast Cancer

EP: 2.Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

EP: 3.Preoperative Monitoring and Surgical Options for HER2+ Patients

EP: 4.Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

EP: 5.Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

EP: 6.Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

EP: 7.Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP: 8.Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

EP: 9.Overview of DESTINY-Breast06

Now Viewing

EP: 10.Clinical Perspectives on Managing ILD Related to T-DXd

EP: 11.Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

EP: 12.Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

What has your clinical experience been monitoring for T-DXd-related interstitial lung disease (ILD)?
What do you think about the recent data presented about re-challenging patients with T-DXd after resolution of Grade 1 ILD?